Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes
Human Mutation · 13.11.2023 · 2023 · 1-16
DOI: 10.1155/2023/8620557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, erschienen am 13.11.2023. Verfasst von Michael R Fiorini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada H3A2B4. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Computational Biology, Genetic Predisposition to Disease, Genetic Variation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Montreal Neurological Institute-Hospital, Michael J. Fox Foundation for Parkinson's Research, Brain Canada.
Abstract (Originalsprache)
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease affecting approximately two per 100,000 individuals globally. While there are many benefits to offering early genetic testing to people with ALS, this has also led to an increase in the yield of novel variants of uncertain significance in ALS-associated genes. Computational (in silico) predictors, including REVEL and CADD, are widely employed to provide supporting evidence of pathogenicity for variants in conjunction with clinical, molecular, and other genetic evidence. However, in silico predictors are developed to be broadly applied across the human genome; thus, their ability to evaluate the consequences of variation in ALS-associated genes remains unclear. To resolve this ambiguity, we surveyed 20 definitive and moderate ClinGen-defined ALS-associated genes from two large, open-access ALS sequencing datasets (total people with ALS = 8,230 ; controls = 9,671 ) to investigate REVEL and CADD’s ability to predict which variants are most likely to be disease-causing in ALS. While our results indicate a predetermined pathogenicity threshold for REVEL that could be of clinical value for classifying variants in ALS-associated genes, an accurate threshold was not evident for CADD, and both in silico predictors were of limited value for resolving which variants of uncertain significance (VUS) may be likely pathogenic in ALS. Our findings allow us to provide important recommendations for the use of REVEL and CADD scores for variants and indicate that both tools should be used with caution when attempting to evaluate the pathogenicity of VUSs in ALS genetic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada H3A2B4.
- Department of Human Genetics, McGill University, Montreal, Quebec, Canada H3A0G4.
- Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada H3A0G4.
ORCID-Profile: Allison A Dilliott, Sali M K Farhan
Förderung
- Montreal Neurological Institute-Hospital
- Michael J. Fox Foundation for Parkinson's Research
- Brain Canada
- ALS Canada
- Fonds de Recherche Santé Québec
- Canadian Institutes of Health Research
Zitieren
APA
Fiorini, M. R., Dilliott, A. A., & Farhan, S. M. K. (2023). Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes. Human Mutation, 2023, 1-16. https://doi.org/10.1155/2023/8620557
Vancouver
Fiorini MR, Dilliott AA, Farhan SMK. Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes. Human Mutation. 2023;2023:1-16. doi:10.1155/2023/8620557
BibTeX
@article{Fiorini2023,
author = {Fiorini, Michael R and Dilliott, Allison A and Farhan, Sali M K},
title = {Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes},
journal = {Human Mutation},
year = {2023},
volume = {2023},
pages = {1--16},
doi = {10.1155/2023/8620557}
}
EUVIMED